<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315054</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-CGH-6014</org_study_id>
    <secondary_id>CN_09_217</secondary_id>
    <nct_id>NCT01315054</nct_id>
  </id_info>
  <brief_title>A Methadone Maintenance Treatment Outcome Study in Three Provinces in China</brief_title>
  <official_title>A Methadone Maintenance Treatment Outcome Study in Three Provinces in China: Comparative Evaluation of the Impact of an Intensive Health Care Provider Training Program Combined With Expanded Services on Treatment Retention, Heroin Use, Methadone Dosing and HIV Risk Practices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for AIDS/STD Control and Prevention, China CDC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methadone treatment has became one of main actions taken in China to control the spread of
      HIV among drug users. However，the average methadone dose used is relatively low. An intensive
      methadone maintenance treatment (MMT) provider training on methadone dosage may be effective
      in increasing the methadone dose levels prescribed to new patients. The study will evaluate
      the effectiveness of a tailored education program for MMT service providers using subsequent
      methadone dose prescribed to new patients. The effects of methadone dose, with and without
      the inclusion of additional psychosocial services, will then be measured through MMT
      retention and illicit opioid use.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MMT retention rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Illicit opioid use rate</measure>
    <time_frame>12 months</time_frame>
    <description>by urinalysis and self-report</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV, HCV, syphilis and HSV-2 infection seroconversion rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High risk needle practice</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High risk sexual practice</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life（WHO Quality of Life -BREF）</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">7700</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis C</condition>
  <condition>Syphilis</condition>
  <condition>Herpes Simplex Type II</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Using currently practiced methadone dosage prescription methods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMT provider dosage training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive health care provider training on prescribing methadone dosage based on national guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMT provider dosage training/counseling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive health care provider training on prescribing methadone dosage, plus providing on-site psychosocial counseling services and peer support to clients .</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MMT provider dosage training</intervention_name>
    <description>Training on methadone dosing provided to health care providers working in methadone maintenance clinics</description>
    <arm_group_label>MMT provider dosage training</arm_group_label>
    <arm_group_label>MMT provider dosage training/counseling</arm_group_label>
    <other_name>training</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>targeted counseling</intervention_name>
    <description>targeted counseling provided to methadone maintenance clinic attendees</description>
    <arm_group_label>MMT provider dosage training/counseling</arm_group_label>
    <other_name>counseling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>national guidelines</intervention_name>
    <description>Provided a hard copy of the existing national guidelines for methadone dosing</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>MMT provider dosage training</arm_group_label>
    <arm_group_label>MMT provider dosage training/counseling</arm_group_label>
    <other_name>dosing guidelines</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  client participants will include both men and women who are opiate-dependent drug
             users who started MMT not more than one month prior to enrollment in the study

          -  18 years of age or older

          -  residing in the study areas
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Bulterys, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>US CDC GAP China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center for HIV/STD Prevention and Control, China CDC</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>March 13, 2014</last_update_submitted>
  <last_update_submitted_qc>March 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IDUs</keyword>
  <keyword>high risk behaviors</keyword>
  <keyword>HIV</keyword>
  <keyword>MMT dosage and retention</keyword>
  <keyword>psychosocial services</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Syphilis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

